ArticleJCO oncology practice2026
Gender Disparities in Citations and Altmetric Attention Score in Oncology.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAltmetric Attention Score (AAS) is a measure of the quantity of attention that a scholarly work receives, and evidence about gender gaps in AAS in oncology is lacking. Our objective was to analyze potential disparities in the AAS within oncology by comparing research publications authored by women first and last authors with those authored by men. Secondarily, we aimed to quantify the extent of over-/undercitation by gender. MATERIALS AND
methodsThe initial data set was compiled from the Altmetric database through Application Programming Interface (API) using oncology-related search terms. Author gender categories were assigned on the basis of the Gender Guesser API. For example, those with first and last authors labeled woman were categorized as woman first author/woman last author (WW). Over-/undercitation was calculated using observed citations and expected citations. Analyses were completed both for the oncology literature as a whole and for prominent subspecialty peer-reviewed journals.
resultsOur search yielded 652,834 articles published between January 1, 2009, and January 31, 2024. For AAS, women in the first author position had a 15.2% lower score compared with men counterparts and women in the last author position had an 8.3% lower score than men (
conclusionSignificant gender disparities in citation rates and AAS exist across various fields within oncology. This highlights a systemic issue where woman-authored research is undercited and receives less attention compared with man-authored work, with the potential to affect career advancement, funding opportunities, and academic recognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.